Search - tctmd.com

Displaying 621 - 640 of 1909

Sort: Relevancy | Date

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

News Conference News EuroPCR 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

Yael L. Maxwell

May 22, 2017

Slimmest Stent to Date Looks Promising in Small Study

News Conference News EuroPCR 2017

Slimmest Stent to Date Looks Promising in Small Study

May 19, 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

News Conference News EuroPCR 2017

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

Michael O'Riordan

May 18, 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

News Conference News EuroPCR 2017

FFR-SEARCH Explores Potential of Physiologic Assessment After PCI

May 18, 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

News Conference News SCAI 2017

Minority Women Face 50% Increased Risk of Death/MI After PCI Compared With White Men at 1 Year

May 18, 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

News Conference News SCAI 2017

Bioresorbable Scaffolds: Where Do We Go From Here?

May 15, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

May 05, 2017

Absorb BVS Recalled in Australia From All Centers Not Studying Device

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

May 03, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

Cardiac Intensive Care Units Face an Ever More Complex Patient Population

News Daily News

Cardiac Intensive Care Units Face an Ever More Complex Patient Population

April 28, 2017

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

April 24, 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.